Pemvidutide has the potential to be the first incretin agent to achieve statistical significance in MASH resolution and ...

Millions of people around the world benefit from weight loss drugs based on the incretin hormone GLP-1. These drugs also improve kidney function, reduce the risk of fatal cardiac events, and are ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and EuropeCompleted ZYNQUISTA™ FDA ...

This surprising discovery opened new possibilities for using peptide medications for weight loss. But how exactly do they work? Your body naturally produces the hormones GLP-1 and GIP, known as ...

"The GLP1s are relatively new and are being rolled-out as scale. We have no idea what damage 20 years of drug-induced ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 20 ...

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced the close of a $215 million Series B ...

Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

For Q3 2024, Aristotle Atlantic’s Large Cap Growth Composite posted a total return of 1.26% gross of fees, underperforming ...